Quoin Pharmaceuticals, Ltd. - American Depositary Shares, each representing thirty-five (35) Ordinary Shares, no par value per share (QNRX)

Q: What does CUSIP 74907L409 represent in this 13F holders report?

CUSIP 74907L409 is the security identifier for QNRX - Quoin Pharmaceuticals, Ltd. - American Depositary Shares, each representing thirty-five (35) Ordinary Shares, no par value per share used to aggregate holder disclosures.

Q: How many institutions held QNRX - Quoin Pharmaceuticals, Ltd. - American Depositary Shares, each representing thirty-five (35) Ordinary Shares, no par value per share in Q4 2025?

18 institutional investors reported QNRX - Quoin Pharmaceuticals, Ltd. - American Depositary Shares, each representing thirty-five (35) Ordinary Shares, no par value per share for Q4 2025. Use the holders table for investor-level position and value details.

CUSIP: 74907L409

Q4 2025 13F Holders as of 31 Dec 2025

Type / Class: Equity / American Depositary Shares, each representing thirty-five (35) Ordinary Shares, no par value per share
Shares outstanding: 843,913
Total 13F shares: 842,827
Share change: +841,336
Total reported value: $12,161,983
Price per share: $14.43
Number of holders: 18
Value change: +$12,140,475
Number of buys: 18

Quarterly Holders Quick Answers

What is CUSIP 74907L409?
CUSIP 74907L409 identifies QNRX - Quoin Pharmaceuticals, Ltd. - American Depositary Shares, each representing thirty-five (35) Ordinary Shares, no par value per share in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Next holder-history checks

These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.

Back to full security ownership history for the broader multi-quarter picture.
Latest 13F filings for newly reported positions across managers.
Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
SEC investors directory for manager drilldown.

Explore More Reporting Periods

Jump to adjacent filing periods for faster comparison and easier crawl discovery.

Newer quarter: Q1 2026
Previous quarter: Q3 2025

Recent filing periods for CUSIP 74907L409:

Q1 2026 Q4 2025 Q3 2025 Q2 2025 Q1 2025

Top shareholders of QNRX - Quoin Pharmaceuticals, Ltd. - American Depositary Shares, each representing thirty-five (35) Ordinary Shares, no par value per share (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.

Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

Holder	Source	Role / Reporting	Ownership %	Shares	Holdings Value	12M Net Δ	As of	Details
Woodline Partners LP	13D/G	—	9.5%	2,785,370	$38,298,838	$0	31 Dec 2025	13D/G
INTEGRATED CORE STRATEGIES (US) LLC	13D/G	—	4.6%	2,618,595	$36,005,681	+$9,858,888	31 Dec 2025	13D/G
ARMISTICE CAPITAL, LLC	13D/G	—	5%	1,081,183	$7,049,313	$0	31 Mar 2025	13D/G
Aberdeen Group plc	13D/G	—	8.9%	75,000	$1,082,250	$0	31 Dec 2025	13D/G
Resolute Capital Asset Partners LLC	13D/G	—	8.5%	50,000	$671,000	$0	10 Oct 2025	13D/G
ADAR1 Capital Management, LLC	13D/G	—	6.9%	58,230	$483,309	$0	31 Dec 2025	13D/G
Denise P. Carter	13D/G	Denise Carter	4.9%	939,238	$244,202	+$82,374	27 Jan 2025	13D/G
Michael Myers	13D/G	—	4.9%	939,230	$244,200	+$82,331	27 Jan 2025	13D/G
Gordon Dunn	3/4/5	Chief Financial Officer	— mixed-class rows	734,513 mixed-class rows	$67,985	—	23 Dec 2024	3/4/5
RHUMBLINE ADVISERS	13F	Company	0.14%	1,210	$8,696	—	30 Sep 2025	13F
GAMMA Investing LLC	13F	Company	0.03%	278	$1,999	—	30 Sep 2025	13F
SBI Securities Co., Ltd.	13F	Company	0%	2	$14	—	30 Sep 2025	13F
UBS Group AG	13F	Company	0%	1	$7	—	30 Sep 2025	13F

Institutional Holders of Quoin Pharmaceuticals, Ltd. - American Depositary Shares, each representing thirty-five (35) Ordinary Shares, no par value per share (QNRX) as of Q4 2025

As of 31 Dec 2025, Quoin Pharmaceuticals, Ltd. - American Depositary Shares, each representing thirty-five (35) Ordinary Shares, no par value per share (QNRX) was held by 18 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 842,827 shares. The largest 10 holders included Ikarian Capital, LLC, Woodline Partners LP, Stonepine Capital Management, LLC, Aberdeen Group plc, MILLENNIUM MANAGEMENT LLC, SummitTX Capital, L.P., BOOTHBAY FUND MANAGEMENT, LLC, ADAR1 Capital Management, LLC, AIGH Capital Management LLC, and Resolute Capital Asset Partners LLC. This page lists 18 institutional shareholders reporting positions in this security for the Q4 2025 filing period.

Investor	Option	Weight %	Change %	Value $	* Price	Shares	Share Change	Activity	Report Period

Compare Q4 2025 vs Q3 2025 Across Filers

Q3 2025 holders

Q4 2025 holders

Holder diff

Investor	Q3 2025 Shares	Q4 2025 Shares	Share Diff	Share Chg %	Q3 2025 Value $	Q4 2025 Value $	Value Diff $	Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend

Quarterly Value Trend

Quarterly Shares Trend

* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.